Structural and functional changes of the heart in patients with diabetic nephropathy undergoing hemodialysis

O. B.  Susla; Z. I.  Litovkina; O. V.  Bushtynska

doi:10.31450/ukrjnd.4(64).2019.06

O. B. Susla I. Horbachevsky Ternopil National Medical University
Z. I. Litovkina I. Horbachevsky Ternopil National Medical University
O. V. Bushtynska I. Horbachevsky Ternopil National Medical University

DOI: https://doi.org/10.31450/ukrjnd.4(64).2019.06

Keywords: hemodialysis, diabetic nephropathy, heart remodeling, eccentric left ventricular hypertrophy, cardiac valve calcification, diastolic myocardial stiffness, systolic dysfunction, pulmonary hypertension.

Abstract

Systematic analysis of cardiac remodeling peculiarities in patients with V D stage of chronic kidney disease (CKD VD) caused by diabetes mellitus is important both in the stratification of cardiovascular risk and in the choice of adequate treatment strategies.

The purpose of the study was to determine the character of structural and functional reconstruction of myocardium in patients with diabetic nephropathy (DN) on maintenance hemodialysis (HD) by identifying left ventricular hypertrophy (LVH), its geometric types, assessment of the severity of heart dysfunction, pulmonary hypertension (PH), as well as determination of frequency of cardiac valve calcification (CVC), development of defects of mitral (MV) and aortic (AV) valves.

Materials and methods. The study included 136 patients on chronic HD (men, 78, age, (53,9±1,0) years, duration of HD, (47,6±4,2) months). Depending on the presence/absence of type 2 diabetes mellitus (DM) with kidney damage, they were divided into two groups: the first one – without DN (n=88); the second one – with DN (n=48). All patients were followed up by standard echocardiography (EchoCG) examination by standard procedure.

Results. LVH was diagnosed in 84.6% of patients with CKD VD stage, significantly more often (93.8 vs. 78.4%, p=0.020) in patients with DN, with the incidence of eccentric LVH in the second group being higher (47.9 vs. 28.4%, p=0.023) than in the first one. Prevalence of pseudonormal and restrictive types of LV diastolic dysfunction (62.5 vs. 28.4%, p<0.001), LV systolic dysfunction (27.1 vs. 9.1%, p=0.006) and PH (64.6 vs 35.2%, p=0.001) were significant in HD patients with DN. CVC was detected in 66.6% of patients with type 2 DM with renal injury with a predominance of calcification of both valves (35.4%) over isolated calcification of MV (MVC) (20.8%) and AV (AVC) (10.4 %). Combined valve calcification in the HD patients of the second group was observed 2.6 times more often (p=0.003) than in the first one. Patients with DN, unlike those without diabetes, were associated with a higher prevalence of stenoses of MV (16.7 vs. 3.4%, p=0.007) and AV (39.6 vs. 15.9%, p=0.004), and insufficiency of MV (66.7 vs. 44.3%, p=0.013) and AV (35.4 vs. 14.8%, p=0.006). The most significant EchoCG parameters that distinguished groups of HD patients with the presence of DN were: left atrial diameter (p<0.001), end-diastolic LV dimension (p<0.001), thickness of interventricular septum (p=0.001), LV myocardial mass index (p=0.001), ratio of transmitral flows in early and late diastole (p=0.009), time of deceleration of early diastolic transmitral blood flow (p<0.001), LV ejection fraction (p=0.009), diameter of the right ventricle (RV) (p=0.003), diameter (p=0.007) and mean pulmonary artery pressure (p<0.001).

Conclusions. In patients with CKD VD stage with DN the maladaptive cardiac remodeling with predominance of unfavorable types (eccentric (to a greater extent) and concentric) LV hypertrophy, RV dilatation, PH, expressive of LV diastolic and systolic dysfunction, large-scale combined MVC and AVC occurs, which, in turn, leads to the formation of valve defects, can contribute to the progression of diastolic myocardial stiffness and heart failure.

Downloads

Download data is not yet available.

References

1. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable disease. Kidney Int. 2011;80(12):1258-1270. doi: 10.1038 / кі.2011.368.

2. Topchii I, Denisenko V, Kirienko O, Semenovykh P, Yakimenko Yu, Mazii V, et al. Relationship of the condition of the myocardium with infringements the calcium and phosphorus metabolism in patients with diabetic nephropathy. Ukr. J. Nephr. Dial. 2017;2(54):27-32. doi: 10.31450/ukrjnd.2(54).2017.06 [In Ukrainian].

3. Belchina Yu, Sokolova L. L-arginine in the treatment of patients with diabetes mellitus and diabetic cardiomyopathy. Endokrynologia. 2018;1(23):60-64 [In Russian].

4. Nardi E, Palermo A, Mulè G, Cusimano P, Cottone S, Cerasola G. Impact of type 2 diabetes on left ventricular geometry and diastolic function in hypertensive patients with chronic kidney disease. J Hum Hypertens. 2011;25(3):144-151. doi: 10.1038/jhh.2010.96.

5. Maiello M, Zito A, Carbonara S, Ciccone MM, Palmiero P. Left ventricular mass, geometry and function in diabetic patients affected by coronary artery disease. J Diabetes Complications. 2017;31(10):1533-1537. doi: 10.1016/j.jdiacomp.2017.06.014.

6. Nishimura M, Hashimoto T, Kobayashi H, Fukukda T, Okino K, Yamamoto N, et al. Possible involvement of TNF-alpha in left ventricular remodeling in hemodialysis patients. J Nephrol. 2003;16(5):641-649.

7. Suslova O, Zubeeva G, Kuzmenko U, Kharlamova O, Suslova A, Monakhova L, et al. Left ventricular myocardial remodeling in patients with end- stage chronic renal disease corrected by program hemodialysis. Sovrem Technol Med. 2014;6(4):160-166.

8. Barberato SH, Bucharles SG, Sousa AM, Costantini CO, Costantini CR, Pecoits-Filho R.. Prevalence and prognostic impact of diastolic dysfunction in patients with chronic kidney disease on hemodialysis. Arq Bras Cardiol. 2010;94(4):457-462.

9. Hung KC, Lee CH, Chen CC, Chu CM, Wang CY, Hsieh IC, et al. Advanced left ventricular diastolic dysfunction in uremic patients with type 2 diabetes on maintenance hemodialysis. Circ J. 2012;(76)10:2380-2385. doi: 10.1253/circj.CJ-12-0471.

10. He Y, Wang Y, Luo X, Ke J, Du Y, Li M. Risk factors for pulmonary hypertension in maintenance hemodialysis patients: a cross-sectional study. Int Urol Nephrol. 2015;47(11):1889-1897. doi: 10.1007/s11255-015-1119-5.

11. Matsuo H, Dohi K, Machida H, Takeuchi H, Aoki T, Nishimura H, et al. Echocardiographic assessment of cardiac structural and functional abnormalities in patients with end-stage renal disease receiving chronic hemodialysis. Circ J. 2018;82(2):586-595. doi: 10.1253/circj.CJ-17-0393.

12. Rossi A, Targher G, Zoppini G, Cicoira M, Bonapace S, Negri C, et al. Aortic and mitral annular calcifications are predictive of all-cause and cardiovascular mortality in patients with type 2 diabetes. Diabetes Care. 2012;35(8):1781-86. doi: 10.2337/dc12-0134.

13. Sayarlioglu H, Acar G, Sahin M, Altunoren O, Coskun Y, Nacar AB, et al. Prevalence and risk factors of valvular calcification in hemodialysis patients. Iran J Kidney Dis. 2013;7(2):129-134.

14. Lang, RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong, A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39. doi: 10.1016/j.echo.2014.10.003.

15. Nagueh SF, Smiseth OA,. Appleton CP, Byrd III BF, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277-314. doi: 10.1016/j.echo.2016.01.011.

16. Vylkenskhof U, Kruk Y. Spravochnyk po ekhokardyohrafyy: perevod s nemetskoho. М.: Med Lyt; 2008. 240 s. [In Russian].

17. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr. 2009;22(1):1-23. doi: 10.1016/j.echo.2008.11.029.

18. Hwang HS, Cho JS, Hong YA, Chang YK, Kim SY, Shin SJ, et al. Vascular calcification and left ventricular hypertrophy in hemodialysis patients: interrelationship and clinical impacts. Int J Med Sci. 2018;15(6):557-563. doi: 10.7150/ijms.23700.

19. Lovic D, Erdine S, Catakoğlu AB. How to estimate left ventricular hypertrophy in hypertensive patients. Anadolu Kardiyol Derg. 2014;14(4):389-395. doi: 10.5152/akd.2014.5115.

20. Papademetriou V. Geometric patterns of left ventricular hypertrophy: Is geometry alone to be blamed? Hellenic J Cardiol. 2017;58(2):143-145. doi: 10.1016/j.hjc.2017.05.010.

21. Susla O. Activity of chronic inflammation and endothelial damage in patients with cardiac valve calcification in dialysis-dependent chronic kidney disease. Ukr. J. Nephr. Dial. 2014;4(44):59-64 [In Ukrainian].

22. Nishimura M, Hashimoto T, Kobayashi H, Fukuda T, Okino K, Yamamoto N, et al. Association between cardiovascular autonomic neuropathy and left ventricular hypertrophy in diabetic haemodialysis patients. Nephrol Dial Transplant. 2004;19(10):2532-2538. doi: 10.1093/ndt/gfh361.

23. Nubé MJ, Hoekstra T, Doganer V, Bots ML, Blankestijn PJ, van den Dorpel M, et al. Left ventricular geometric patterns in end-stage kidney disease: Determinants and course over time. Hemodial Int. 2018;22 (3):359-368. doi: 10.1111/hdi.12644.

24. Susla O, Litovkina Z. Metabolic factors of cardiovascular risk in patients with diabetic nephropathy who undergo programmed hemodyalisis. Visnyk naukovykh doslidzhen. 2018;4(93):55-60. doi 10.11603/2415-8798.2018.4.9813 [In Ukrainian].

25. Zapolski T, Wysokiński A, Janicka L, Grzebalska A, Ksiazek A. Aortic stiffness and valvular calcifications in patients with end-stage renal disease. Pol Arch Med Wewn. 2008;118(3):111-118.

26. Inoue T, Ogawa T, Iwabuchi Y, Otsuka K, Nitta K. Left ventricular end-diastolic diameter is an independent predictor of mortality in hemodialysis patients. Ther Apher Dial. 2012;16(2):134-141. doi: 10.1111/j.1744-9987.2011.01048.x.

27. Kyyak YuH., Kyyak HYu, Barnett OYu. Specifics of diabetic cardiomyopathy in the cases of concomitant cardiovascular diseases:clinical and ultrastructural examinations. Mizhnarodnyi endokrynolohichnyi zhurnal. 2016;5:33-38. doi: 10.22141/2224-0721.5.77.2016.78751 [In Ukrainian].

28. Bellasi A, Ferramosca E, Ratti C, Block G, Raggi P. Cardiac valve calcification is a marker of vascular disease in prevalent hemodialysis patients. J Nephrol. 2012;25(2):211-218. doi: 10.5301/JN.2011.8446.

29. Leskinen Y, Paana T, Saha H, Groundstroem K, Lehtimäki T, Kilpinen S, et al. Valvular calcification and its relationship to atherosclerosis in chronic kidney disease. J Heart Valve Dis. 2009;18(4):429-438.

30. Głowińska I, Grochowski J, Małyszko J. Cardiovascular complications in patients with diabetic nephropathy receiving pharmacological versus renal replacement therapy. Pol Arch Med Wewn. 2008;118(7-8):404-412.

31. Susla O, Litovkina Z, Gozhenko A, Shved M, Danyliv S. Hypomagnesemia as important component of atherosclerosis progression in type 2 diabetic patients with end-stage renal disease. CardioNephrology 2019, March 12-14, Rome, Italy, Abstract.

32. Karakitsos D, De Groot E, Patrianakos AP, Parthenakis F, Boletis J, Karabinis A, et al. Adiponectin and cardiovascular remodeling in end-stage renal disease and co-morbid diabetes mellitus. Am J Nephrol. 2006;26(4):340-347. doi: 10.1159/000094403.

33. Wang C1, Jiang L, Feng S, Shi Y, Shen H, Shi X, et al. Risk factor analysis of calcification in aortic and mitral valves in maintenance peritoneal dialysis patients. Kidney Blood Press Res. 2013;37(4-5):488-495. doi: 10.1159/000355729.

34. Sharma R, Pellerin D, Gaze DC, Mehta RL, Gregson H, Streather CP, et al. Mitral annular calcification predicts mortality and coronary artery disease in end stage renal disease. Atherosclerosis. 2007;191(2):348-354. doi: 10.1016/j.atherosclerosis.2006.03.033.

35. Kocinaj D, Gashi M, Berisa M, Korça H, Berisha M, Ramadani N. Echocardiographic assesment of left atrial size in patients with end-stage renal disease. Cardiovascular J Afr. 2009;20(3):183-186.

36. Sise ME, Courtwright AM, Channick RN. Pulmonary hypertension in patients with chronic and end-stage renal disease. Kidney Int. 2013;84(4):682-692. doi: 10.1038/ki.2013.186.

37. Yu TM, Chen YH, Hsu JY, Sun CS, Chuang YW, Chen CH, et al. Systemic inflammation is associated with pulmonary hypertension in patients undergoing haemodialysis. 2009;24(6):1946-1951. doi: 10.1093/ndt/gfn751.

38. Dudar I. Driianska V, Hryhorieva Ye. Interleukin 10, body mass index and serum albumin in chronic kidney disease stage 5D patients. Ukr. J. Nephr. Dial. 2013;4(40):30-33 [In Ukrainian]. doi: 10.31450/ukrjnd.4(40).2013.04.